For the Inventor, By the Inventor

Enter assignee name

Medshine Discovery Inc.

USPTO Granted Patents = 65

CIPO Patents = 9

EPO Patents = 36

Forward Citations = 53

Loading Chart...

Loading Chart...

169 inventors (with patents filed for the assignee):

Shuhui Chen (52 out of 197 patents)

Jian Li (32 out of 200 patents)

Charles Z Ding (14 out of 50 patents)

4. Guoping Hu (12 out of 32 patents)

5. Lingyun Wu (10 out of 24 patents)

6. Haiying He (8 out of 53 patents)

7. Wenyuan Qian (7 out of 19 patents)

8. Lihong Hu (7 out of 29 patents)

9. Kevin X Chen (7 out of 29 patents)

10. Yunfu Luo (7 out of 33 patents)

11. Zhigan Jiang (6 out of 18 patents)

12. Zhaoguo Chen (6 out of 8 patents)

13. Shuhui Chen (6 out of 115 patents)

14. Yanxin Yu (5 out of 5 patents)

15. Maoyi Lei (5 out of 9 patents)

Core Competencies:

Phenylpropionamide Compound

Acetophenone Oxime Compound

KRAS G12C Inhibitor

RIP-1 Kinase Inhibitor

SGLT1 Inhibitor

HER2 Inhibitors

MDM2-p53 Inhibitors

c-MET Inhibitor

LSD1 Inhibitors

CSF-1R Inhibitor

mTORC 1/2 Dual Inhibitors

Prostacyclin Receptor Agonist

65 patents: Sort by Forward Citations

1. 12479800 - Phenylpropionamide compound and use thereof (2025-11-25),

2. 12479794 - Acetophenone oxime compound and application thereof (2025-11-25),

3. 12421236 - Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor (2025-09-23),

4. 12351590 - Pyrrolopyrimidine compound and use thereof (2025-07-08),

5. 12351587 - Bicyclic compound as RIP-1 kinase inhibitor and application thereof (2025-07-08),

6. 12338218 - Crystal form of benzimidazole-2-one compound, solvate thereof, crystal form of solvate thereof, and preparation method thereof (2025-06-24),

7. 12258367 - Glucoside derivative that acts as SGLT1 inhibitor and application thereof (2025-03-25),

8. 12030897 - Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof (2024-07-09),

9. 11905276 - Bicyclic compound that acts as CRBN protein regulator (2024-02-20),

10. 11814371 - Heterocyclic compound (2023-11-14),

11. 11718610 - Compounds containing benzosultam (2023-08-08),

12. 11702400 - Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors (2023-07-18),

13. 11691974 - 3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors (2023-07-04),

14. 11680070 - Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof (2023-06-20),

15. 11673899 - Crystal form of thieno[2,3-c]pyridazine-4(1H)-one compound, preparation method therefor and use thereof (2023-06-13),

MEDSHINE DISCOVERY INC. is a biotechnology company focused on the discovery and development of innovative therapeutic solutions. With a team of experienced scientists, we aim to address unmet medical needs and improve patient outcomes. Our research and development efforts are centered around identifying novel drug targets, conducting preclinical testing, and advancing promising drug candidates into clinical trials. Through our dedication to scientific excellence, we strive to bring transformative medicines to market and make a positive impact on global healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

65 Patents

#10 in Jiangsu

#443 in China

#10,892 in the World

Medshine Discovery Inc.

Forward Citations = 53

169 inventors:

Shuhui Chen (52 out of 197 patents)

Jian Li (32 out of 200 patents)

Charles Z Ding (14 out of 50 patents)

4. Guoping Hu (12 out of 32 patents)

5. Lingyun Wu (10 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…